ARDT241220C2500
- 0.00
- 0.000.00%
Ardent Health Partners Newsroom
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $22
RBC Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $23
Ardent Health Partners Is Maintained at Outperform by Leerink Partners
Loop Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $21
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
RBC Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $23
Ardent Health Partners, Inc.: Strong Financial Performance and Growth Potential Drive Buy Rating
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
BofA Securities Maintains Ardent Health Partners(ARDT.US) With Hold Rating, Maintains Target Price $19
Mizuho Securities Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Mizuho Securities Keeps Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Ardent Health Partners Cut to Neutral From Buy by B of A Securities
Ardent Health Partners Analyst Ratings
BofA Securities Initiates Ardent Health Partners(ARDT.US) With Hold Rating, Announces Target Price $19
RBC Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $23
Ardent Health Partners Price Target Maintained With a $24.00/Share by Stephens & Co.
Ardent Health Partners Analyst Ratings
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27